Physician

Adetoye Lufadeju, M.D

According to 2025 Medicare claims, Adetoye Lufadeju, M.D (NPI: 1023327426) practices nephrology in the Greensboro-High Point, NC market, with the plurality of this provider's patient population coming from Guilford, NC. This provider's primary affiliated billing organization is WAKE FOREST HEALTH NETWORK LLC (NPI: 1083971485; TIN: 561935767) and primary practice location at 27265-8356. Lufadeju is affiliated with the Advocate Physician Partners Accountable Care, Inc. (ACO ID: A1033), participating under the MSSP model.

Lufadeju's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 283 traditional Medicare patients, billed 1,209 HCPCS/CPT codes, and received $117,218 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 3,006 prescription claims across 514 beneficiaries totaling $187,413 in drug costs, led by Veltassa (Patiromer Calcium Sorbitex). DME data shows 212 claims. Open Payments data shows 3 records totaling $264. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $156,212 and ending at $187,413. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $0 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	370	4,484	$177,492
2016	323	3,308	$151,871
2017	333	3,150	$161,325
2018	341	3,301	$176,142
2019	365	3,970	$204,762
2020	318	2,350	$167,502
2021	318	2,064	$170,213
2022	331	1,485	$144,842
2023	294	1,127	$125,861
2024	283	1,209	$117,218

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	262	2,508	$156,212
2016	280	2,699	$204,296
2017	277	2,670	$199,703
2018	305	2,463	$271,155
2019	368	2,403	$155,770
2020	364	2,389	$160,543
2021	414	2,798	$160,603
2022	430	3,034	$249,959
2023	440	2,997	$236,236
2024	514	3,006	$187,413

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	12	$17
2019	N/R	N/R	N/R
2020	N/R	22	$820
2021	N/R	40	$4,681
2022	N/R	191	$32,938
2023	N/R	181	$18,670
2024	N/R	212	$7,475

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	37	41	$129
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	72	241	$87
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	161	239	$82
90935	Hemodialysis procedure with physician evaluation	26	83	$52
81003	Automated urinalysis test	50	51	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Veltassa	Patiromer Calcium Sorbitex	12	434	$12,096
Sevelamer Carbonate	Sevelamer Carbonate	62	3,028	$7,927
Torsemide	Torsemide	197	13,876	$6,138
Januvia	Sitagliptin Phosphate	11	330	$6,070
Calcium Acetate	Calcium Acetate	76	3,446	$5,271

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	17	$3,909
J7518	Mycophenolic acid, oral, 180 mg	N	N/R	27	$1,525
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	69	$815
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	37	$659
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	19	$536

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	3	$264	ACADIA Pharmaceuticals Inc
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adetoye Lufadeju, M.D?

Tedicare shows public-source Medicare data for Adetoye Lufadeju, M.D (NPI 1023327426), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adetoye Lufadeju, M.D have ACO affiliation data?

Adetoye Lufadeju, M.D is shown with ACO affiliation data for Advocate Physician Partners Accountable Care, Inc. (MSSP, ACO ID A1033).

What billing organization is linked to Adetoye Lufadeju, M.D?

Adetoye Lufadeju, M.D is linked to WAKE FOREST HEALTH NETWORK LLC (billing NPI 1083971485) in the available physician profile data.

Does Adetoye Lufadeju, M.D have Open Payments data?

Adetoye Lufadeju, M.D has 3 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.